Suppr超能文献

()-1-(4-甲基哌嗪-1-基)-3-(5-硝基呋喃-2-基)丙-2-烯-1-酮对p53的共价修饰

Covalent Modification of p53 by ()-1-(4-Methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one.

作者信息

Brown Kate, Robello Marco, Perciaccante Andrew J, Dinan Jerry C, Maity Tapan K, Lyons Gaelyn C, Kumar Jay P, Durell Stewart R, Tagad Harichandra D, Schilling Daniel, Nikolayevskiy Herman, O'Connor Robert, Appella Ettore, Appella Daniel H, Jenkins Lisa M

机构信息

Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States.

Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20814, United States.

出版信息

ACS Pharmacol Transl Sci. 2024 Oct 14;7(11):3559-3572. doi: 10.1021/acsptsci.4c00447. eCollection 2024 Nov 8.

Abstract

is commonly mutated in cancer, giving rise to loss of wild-type tumor suppressor function and increases in gain-of-function oncogenic roles. Thus, inhibition of mutant p53 and reactivation of wild-type function represents a potential means to target diverse tumor types. ()-1-(4-Methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one (NSC59984), first identified from a high-throughput screen, induces wild-type p53 signaling and antiproliferative effects while inhibiting mutant p53 gain-of-function activities. Here, we investigate the specific mechanism of action of NSC59984 against p53. We found that NSC59984 reacts with thiols via an unusual Michael addition at the α-carbon. Covalent modification of p53 Cys124 and Cys229 was observed both following reaction and upon treatment of cells. Finally, we used a biotinylated form of NSC59984 and, separately, thermal proteome profiling to examine off-target effects, identifying several metabolic proteins involved in cellular metabolism as potential targets. These results demonstrate that covalent modification of p53 by NSC59984 leads to increased wild-type activity and suggest that potential reaction with metabolic enzymes may contribute to antiproliferative function.

摘要

在癌症中通常发生突变,导致野生型肿瘤抑制功能丧失,并增加功能获得性致癌作用。因此,抑制突变型p53并重新激活野生型功能是针对多种肿瘤类型的一种潜在手段。()-1-(4-甲基哌嗪-1-基)-3-(5-硝基呋喃-2-基)丙-2-烯-1-酮(NSC59984),最初从高通量筛选中鉴定出来,可诱导野生型p53信号传导和抗增殖作用,同时抑制突变型p53的功能获得性活性。在此,我们研究了NSC59984针对p53的具体作用机制。我们发现NSC59984通过在α-碳上进行异常的迈克尔加成与硫醇反应。在反应后以及细胞处理后均观察到p53的Cys124和Cys229发生共价修饰。最后,我们使用了生物素化形式的NSC59984,并分别通过热蛋白质组分析来检查脱靶效应,确定了几种参与细胞代谢的代谢蛋白作为潜在靶点。这些结果表明,NSC59984对p53的共价修饰导致野生型活性增加,并表明与代谢酶的潜在反应可能有助于抗增殖功能。

相似文献

1
Covalent Modification of p53 by ()-1-(4-Methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one.
ACS Pharmacol Transl Sci. 2024 Oct 14;7(11):3559-3572. doi: 10.1021/acsptsci.4c00447. eCollection 2024 Nov 8.
2
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
3
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
6
Active body surface warming systems for preventing complications caused by inadvertent perioperative hypothermia in adults.
Cochrane Database Syst Rev. 2016 Apr 21;4(4):CD009016. doi: 10.1002/14651858.CD009016.pub2.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
8
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
10
Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension.
Cochrane Database Syst Rev. 2022 Jun 10;6(6):CD013817. doi: 10.1002/14651858.CD013817.pub2.

本文引用的文献

2
An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53.
Eur J Med Chem. 2024 Feb 5;265:116121. doi: 10.1016/j.ejmech.2024.116121. Epub 2024 Jan 3.
3
Pharmacological reactivation of p53 in the era of precision anticancer medicine.
Nat Rev Clin Oncol. 2024 Feb;21(2):106-120. doi: 10.1038/s41571-023-00842-2. Epub 2023 Dec 15.
4
Small-molecule correctors and stabilizers to target p53.
Trends Pharmacol Sci. 2023 May;44(5):274-289. doi: 10.1016/j.tips.2023.02.007. Epub 2023 Mar 22.
5
Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile.
Front Oncol. 2023 Jan 11;12:1094210. doi: 10.3389/fonc.2022.1094210. eCollection 2022.
6
Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials.
Cancers (Basel). 2023 Jan 9;15(2):429. doi: 10.3390/cancers15020429.
7
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation.
Cell Death Dis. 2022 Nov 18;13(11):974. doi: 10.1038/s41419-022-05408-1.
8
Gain of Function (GOF) Mutant p53 in Cancer-Current Therapeutic Approaches.
Int J Mol Sci. 2022 Oct 31;23(21):13287. doi: 10.3390/ijms232113287.
9
A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability.
Cancer Discov. 2023 Jan 9;13(1):56-69. doi: 10.1158/2159-8290.CD-22-0381.
10
A role for bioinorganic chemistry in the reactivation of mutant p53 in cancer.
J Biol Inorg Chem. 2022 Aug;27(4-5):393-403. doi: 10.1007/s00775-022-01939-2. Epub 2022 Apr 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验